THE MANAGEMENT OF SPASTICITY WITH BOTULINUM TOXIN

A working model for treating spasticity with botulinum toxin A has bee n adopted by the National Hospital for Neurology and Neurosurgery in L ondon, United Kingdom. To achieve functional goals with this toxin, al l the factors contributing to spasticity must be considered; the toxin must be given as part of a complete neurorehabilitative programme wit h clear symptomatic or functional goals. Although experience with the use of this agent in spasticity is growing, many functional benefits o f the therapy are still unclear. A trial of botulinum toxin A as part of neurorehabilitation is currently being undertaken at the National H ospital for Neurology and Neurosurgery.